BiotechTube

Ruxolitinib Cream

Phase 2Completed
0 watching 0 views this week⚡ Active
49
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Nonsegmental Vitiligo With Genital Involvement

Conditions

Nonsegmental Vitiligo With Genital Involvement

Trial Timeline

Apr 11, 2023 → Mar 6, 2025

NCT ID
NCT05750823

About Ruxolitinib Cream

Ruxolitinib Cream is a phase 2 stage product being developed by Incyte for Nonsegmental Vitiligo With Genital Involvement. The current trial status is completed. This product is registered under clinical trial identifier NCT05750823. Target conditions include Nonsegmental Vitiligo With Genital Involvement.

Hype Score Breakdown

Clinical
17
Activity
12
Company
7
Novelty
5
Community
5

Clinical Trials (8)

NCT IDPhaseStatus
NCT07049575Phase 1Recruiting
NCT06259669Pre-clinicalRecruiting
NCT05750823Phase 2Completed
NCT05696392ApprovedTerminated
NCT05456529Phase 3Completed
NCT05034822Phase 1Completed
NCT04839380Phase 2Completed
NCT03920852Phase 1Completed

Competing Products

7 competing products in Nonsegmental Vitiligo With Genital Involvement

See all competitors
ProductCompanyStageHype Score
Ritlecitinib + Ritlecitinib + PlaceboPfizerPhase 3
76
Ritlecitinib + PlaceboPfizerPhase 3
76
Ruxolitinib Cream + Vehicle CreamIncytePhase 3
74
Ruxolitinib Cream + Vehicle CreamIncytePhase 3
74
INCB054707 + PlaceboIncytePhase 2
49
Povorcitinib + PlaceboIncytePhase 3
74
Povorcitinib + PlaceboIncytePhase 3
74

Other Products from Incyte

ruxolitinib creamApproved
82
Itacitinib + Placebo + Prednisone + MethylprednisolonePhase 3
74
Povorcitinib + PlaceboPhase 3
74
Ruxolitinib Cream + Vehicle CreamPhase 3
74
Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)Phase 3
74